PROPORTION OF DEPRESSION IN NON-MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS PATIENTS AT CIPTO MANGUNKUSUMO GENERAL HOSPITAL AND ITS RELATED FACTORS

Reinaldo Alexander¹, Rudi Putranto², Cleopas Martin Rumende³, Ikhwan Rinaldi⁴, Hamzah Shatri²

¹Internal Medicine Department, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital

²Psychosomatic and Critical Care Division of Internal Medicine Department, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital
 ³ Respirology and Critical Care Division of Internal Medicine Department, Cipto Mangunkusumo National General Hospital Indonesia
 ⁴Medical Hematology-Oncology Division of Internal Medicine Department, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital

ABSTRACT

Aim: To determine the proportion of depression in non-multidrug-resistant pulmonary TB patients at Cipto Mangunkusumo General Hospital and also its related factors. **Method:** A cross-sectional study of 122 non-multidrug-resistant pulmonary TB patients was done at outpatient department of Cipto Mangunkusumo General Hospital from August to October 2018. The diagnosis of depression was made by interview according to Diagnostic and Statistical Manual of Mental Disorder-V (DSM-V) criteria, and severity of depression is determined using Beck Depression Inventory-II (BDI-II). Bivariate and multivariate analysis using the logistic regression test was done using SPSS.

Results: From 122 patients with non-multidrug-resistant pulmonary TB, the proportion of depression is 48,4%. There are 2 factors related to depression in non-multi-drug resistant pulmonary TB patients, which are the occurrence of side effects from TB treatment (p < 0,001; OR 7,13; 95% CI 2,67 - 19,03), and the presence of other chronic disease (p < 0,001; OR 12,90; 95% CI 3,87 - 4,01 - 41,50).

Conclusion: The proportion of depression in non-multidrug-resistant pulmonary TB patients at Cipto Mangunkusumo General Hospital is 48,4%. The occurrence of TB treatment side effects, and the presence of chronic disease comorbidities are related to depression in non-multidrug-resistant pulmonary TB patients.

Keywords: depression, non-multi-drug resistant pulmonary Tuberculosis

ABSTRAK

Tujuan: Mengetahui proporsi depresi pada pasien TB paru tidak resisten obat di RS Cipto Mangunkusumo serta mengetahui faktor-faktor apa saja yang berhubungan dengan kejadian depresi pada pasien TB paru.

Metode: Studi dengan desain potong lintang terhadap 122 pasien TB paru tidak resisten obat yang berobat jalan di poliklinik paru RS Cipto Mangunkusumo dari bulan Agustus hingga Oktober 2018. Diagnosis depresi ditegakkan dengan wawancara menurut kriteria diagnosis dari Diagnostic and Statistical Manual of Mental Disorder-V (DSM-V) dan derajat depresi ditentukan menggunakan kuesioner Beck Depression Inventory-II (BDI-II). Analisa bivariat dan multivariat dengan uji regresi logistik dilakukan dengan menggunakan SPSS Hasil: Dari 122 pasien dengan TB paru tidak resisten obat yang menjadi subyek penelitian, didapatkan proporsi depresi sebesar 48,4%. Terdapat dua faktor yang berhubungan dengan kejadian depresi pada pasien TB paru tidak resisten obat yaitu adanya efek samping obat anti TB (p < 0,001; OR 7,13; IK 95% 2,67 -19,03), dan adanya komorbiditas penyakit kronik (p < 0,001; OR 12,90; IK 95% 4,01 - 41,50)

Address for corespondance : Farissa Luthfia, Birry Karim Psychosomatic and Critical Care Division of Internal Medicine Department, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jl.Diponegoro 71, Jakarta 10430, Indonesia Email : reince1985@gmail.com

PROPORTION OF DEPRESSION IN NON-MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS PATIENTS AT CIPTO MANGUNKUSUMO GENERAL HOSPITAL AND ITS RELATED FACTORS Simpulan: Proporsi depresi pada pasien TB paru tidak resisten obat di RS Cipto Mangunkusumo sebesar 48,4%. Adanya efek samping obat anti TB dan komorbiditas penyakit kronik berhubungan dengan kejadian depresi pada pasien TB paru tidak resisten obat.

Kata kunci: depresi, Tuberkulosis paru tidak resisten obat

INTRODUCTION

Depression comorbidity is common in pulmonary Tuberculosis (TB) patients. From a cohort study, the risk of having depression is 1.53 times higher in TB patients.¹ The prevalence of depression in TB patients varies between studies and ranging from 27.7% to 80%.²⁻⁶ A study conducted by Basuki, et al.⁷ found that there are strong linier relationship between depression and treatment compliance in pulmonary TB patients. Low treatment compliance will result in increased morbidity, mortality, re-hospitalization rate and risk of developing Multi Drug Resistant Tuberculosis (MDR-TB).^{2,8-10}

There are many factors contribute to depression. These factors include the sociodemographic profile of TB patients such as older age, female gender, low education level,³ marriage status,¹¹ and low income.² From the clinical aspects of TB infection, being underweight in which body mass index (BMI) < 18,5 kg/m²,³ persistent cough,⁵ still treated in the intensive phase,¹² being on retreatment for TB infection,⁶ having TB treatment side effects,¹³ having multiple chronic disease comorbidities,¹⁴ and more severe TB infection¹⁵ are factors associated with increased risk of having depression in pulmonary TB patients.

Either depression or pulmonary TB condition will activate the inflammation process in the body. Thus increasing the production of proinflammatory cytokines such as *Interleukin-6* (IL-6), *Tumor Necrosis Factor-* α (TNF- α), and *C-Reactive Protein* (CRP).¹⁶ The inflammation state in these conditions can be seen by examining the Neutrophil-Lymphocyte Ratio (NLR). From previous study, patients with depression have increased NLR value. This finding also correlates

to the degree of depression and increased risk of having cardiovascular event.¹⁷

METHOD

This is a cross-sectional study involving 122 non-MDR pulmonary TB patients at the outpatient department of Cipto Mangunkusumo Hospital. The study takes place from August to October 2018. The sample size is determined using the formula for comparing two proportions of independent variables and the formula to compare two means for the NLR variable. From calculation we determined the minimal sample size was 120. We used consecutive sampling technique in this study. The inclusion criteria was adult > 18 years old pulmonary TB patients, who are willing to participate in the study. Meanwhile, the exclusion criteria include having only extra pulmonary TB, MDR TB, HIV comorbidity, being hospitalized for at least 5 days in the last month, and having condition which involved the production of blood cells in the marrow.

The study participants were interviewed for depression symptoms according to the Diagnostic and Statistical Manual of Mental Disorder-V (DSM-V) criteria, and then asked to fill the Beck Depression Inventory II (BDI-II) questionnaire which has been validated before for the Indonesian population.¹⁸ We also obtained blood sample for the NLR evaluation for each participant. Statistical data processed using Statistical Product for Social Science (SPSS) program version 20,0. The bivariate analysis for categorical variables are done using the Chi square method, or using Fischer test if the requirements are not met. For the NLR variable, we used the Mann-Whitney test and the multivariate analysis are done using the logistic regression test.

RESULTS

From August to October 2018, we have 122 study participants who fulfill the inclusion criteria and not met the exclusion criteria. There are no drop out subject All participants are included in the analysis. Depression was found in 59 study participants (48.4%). Mild depression is found in 57,6% depressed subject participant, meanwhile moderate depression found in 27,1%, and severe depression in 15.3% subject with depression. From the BDI-II questionnaire, we found that fatigue is found in all subjects with depression. Other main depressive symptoms include feeling of guilt, sleeping problems, and change of appetite.

The ratio of male and female are 45,8%, and 54,2% respectively. Most of the study participants are more than 40 years old in age (57,4%). Most of them are married, have lower income compared to Jakarta regional minimal wage. The mean for BMI in all study participant are $20,13 \pm 3,506$ kg/m². Most of them (68%) have chronic disease comorbidities. These comorbidities include rheumatic and autoimmune disease in 23,8%, malignancy in 21.3%, hypertension in 19.7%, and diabetes mellitus in 16,4% subjects. Majority of the study participants are first time having pulmonary TB, were in the maintenance phase of TB treatment, have moderate TB symptoms, and no longer have cough symptom. There are 58.2% study participant who experience side effects from TB treatment. The most reported side effects

are nausea, followed by itching and allergic reaction. We found that the NLR value is higher in the depressed group with median value of 2,53 (1,14-9,22), and median of 2,15 (0,95-5,62) in the non-depressed group. The characteristic of study participants can be seen in table 1.

From bivariate analysis, we found that low education (p = 0.029; OR 4.082; 95%CI 1,06-15,65), having TB treatment side effects (p <0,001; OR 6,36; 95%CI 2,84-14,34), and subjects with chronic disease comorbidities (p <0,001; OR 12,66; 95%CI 4,47-35,88) are related to depression in non-MDR pulmonary TB patients. From multivariate analysis, we found that the occurrence of side effects from TB treatment (p < 0,001; OR 7,13; 95% CI 2,67 – 19,03), and the presence of other chronic disease (p < 0,001; OR 12,90; 95% CI 3,87 – 41,50) are related to depression in non-MDR pulmonary TB patients. The bivariate analysis can be seen in table 2, meanwhile the multivariate analysis can be seen in table 3.

Characteristics	N =122	Mean ± SD / median (min-max)
Gender, n (%)		X X
Male	59 (48,4)	
Female	63 (51,6)	
Age (year), n (%)		46 (18-77)
18-29	28 (23)	
30-39	24 (19,7)	
40-49	18 (14,8)	
50-59	32 (26,2)	
≥ 60	20 (16,4)	
Ethnic, n (%)		
Betawi	34 (27,9)	
Sunda	16 (13,1)	
Jawa	31 (25,4)	
Tapanuli	9 (7,4)	
Padang	11 (9)	
Others	21 (17,2)	
Education level, n (%)		
Less than 9 years basic education program	13 (10,7)	
More than 9 years basic education program	109 (89,3)	
Marital status, n (%)		
Single	33 (27)	
Married/had married	89 (73)	
Income status, n (%)		
Low	81 (66,4)	
High	41 (33,6)	
Chronic disease comorbidities, n (%)		
Present	83 (68)	
Absent	39 (32)	

Table 1. Study participant characteristics

Type of comorbidities n (%) 29 (23,8) Rheumatic and autoimmune disease 29 (23,8) Maligrancy 26 (21,3) Hypertension 24 (19,7) Diabetes Melitus 20 (16,4) Others 19 (15,5) Cardiovascular 6 (4,9) Benign hematologic disorder 6 (4,9) Chronic kidney disease 5 (4,1) Ashma 3 (2,5) Stroke 2 (1,6) The treatment for TB, n (%) 1 Yes 40 (32,8) No 82 (67,2) Persistent cough, n (%) 10 (90,2) Yputur results, n (%) 10 (90,2) Sputur results, n (%) 11 (58,2) Absent 51 (41,8) Side effects, n (%) 11 (58,2) Absent 51 (41,8) Side effects, n (%) 10 (80,8) The reaction 37	Characteristics	N =122	Mean ± SD / median (min-max)
\hat{R} elementic and autoimmune disease 29 (23,8) Malignancy 26 (21,3) Hypertension 24 (19,7) Diabetes Melitus 20 (16,4) Others 19 (15,5) Cardiovascular 6 (4,9) Benign hematologic disorder 6 (4,9) Chronic kidney disease 5 (4,1) Asthma 3 (2,5) Thyroid disease 3 (2,5) Stroke 2 (1,6) TB treatment phase, n (%) 1 Intensive 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) Yes Yes 12 (9,8) No 20 (3,2) Persistent cough, n (%) 10 (90,2) Sputum results, n (%) 100 (90,2) Sputum results, n (%) 100 (90,2) No 43 (35,2) TB reatment side effects, n (%) 100 (90,2) No 100 (90,2) Sputum results, n (%) 100 (90,2) Sputum results, n (%) 100 (90,2) No 100 (90,2) Sputum results, n (%) 100 (90,2) S	Type of comorbidities n (%)		
Maingancy 26 (21, 3) Hypertension 24 (19,7) Diabetes Melitus 20 (16,4) Others 19 (15,5) Cardiovascular 6 (4,9) Benign hematologic disorder 6 (4,9) Chronic kirdney disease 5 (4,1) Astma 3 (2,5) Thyroid disease 3 (2,5) Stroke 2 (1,6) B treatment phase, n (%) 1 Intensive 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) 2(3,8) No 82 (67,2) Persistent cough, n (%) 10 (90,2) Spattum results, n (%) 10 (90,2) No 110 (90,2) Spattum results, n (%) 10 (90,2) Spattum results, n (%) 10 (13,1) Negative 63 (51,6) Absent 51 (41,8) Side effects, n (%) 10 (15,6) <td< td=""><td>Rheumatic and autoimmune disease</td><td>29 (23,8)</td><td></td></td<>	Rheumatic and autoimmune disease	29 (23,8)	
Hypértension 24 (19,7) Diabetes Melitus 20 (16,4) Others 19 (15,5) Cardiovascular 6 (4,9) Benign hematologic disorder 6 (4,9) Chronic kidney disease 5 (4,1) Asthma 3 (2,5) Thyroid disease 3 (2,5) Thyroid disease 3 (2,5) Thyroid disease 3 (2,5) Thyroid disease 3 (2,5) Theratment phase, n (%) 1 Intensive 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) 20 (32,8) No 82 (67,2) Persistent cough, n (%) 21 (9,8) No 110 (90,2) Sputum results, n (%) 12 (9,8) No 12 (9,8) No 110 (90,2) Sputum results, n (%) 1 Present 7 (158,2) Absent 51 (41,8) Side effects, n (%) 1 Present 7 (158,5) Allergic reaction 37 (30,3) </td <td>Malignancy</td> <td>26 (21,3)</td> <td></td>	Malignancy	26 (21,3)	
Diabetes Melitus 20 (16.4) Others 19 (15.5) Cardiovascular 6 (4.9) Benign hematologic disorder 6 (4.9) Chronic liver disease 6 (4.9) Chronic kindry disease 5 (4.1) Asthma 3 (2.5) Thyroid disease 3 (2.5) Stroke 2 (1.6) Beneration of the second	Hypertension	24 (19,7)	
Others 19 (15,5) Cardiovascular 6 (4,9) Benign hematologic disorder 6 (4,9) Chronic liver disease 6 (4,9) Chronic dindry disease 5 (4,1) Asthma 3 (2,5) Thyroid disease 3 (2,5) Stroke 2 (1,6) TB treatment phase, n (%) 1 Intensive 4 (3 (3,4)) Maintenance 80 (65,6) Retreatment for TB, n (%) 2 Yes 12 (9,8) No 82 (67,2) Persistent cough, n (%) 10 (90,2) Sputum results, n (%) 10 (90,2) Sputum results, n (%) 10 (90,2) Sputum results, n (%) 10 (90,2) Positive 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 110 (90,2) Present 71 (58,2) Absent 51 (41,8) Gastrointestinal 47 (38,5) Allergic reaction 5 (4,1) Eye probl	Diabetes Melitus	20 (16,4)	
Cardiovascular $6(4,9)$ Benign hematologic disorder $6(4,9)$ Chronic kidney disease $6(4,9)$ Chronic kidney disease $5(4,1)$ Asthma $3(2,5)$ Thyroid disease $3(2,5)$ Stroke $2(1,6)$ B treatment phase, $n(%)$ Intensive Intensive $42(34,4)$ Maintenance $80(65,6)$ Retreatment for TB, $n(%)$ $2(9,8)$ No $10(90,2)$ Sputum results, $n(%)$ $10(8,2,2)$ TB reatment side effects, $n(%)$ </td <td>Others</td> <td>19 (15,5)</td> <td></td>	Others	19 (15,5)	
Benign hematologic disorder 6 (4,9) Chronic kidney disease 6 (4,9) Chronic kidney disease 5 (4,1) Ashma 3 (2,5) Stroke 2 (1,6) Thyroid disease 3 (2,5) Stroke 2 (1,6) TB treatment phase, n (%) 1 Intensive 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) 2 Yes 12 (9,8) No 82 (67,2) Persistent cough, n (%) 10 (90,2) Sputum results, n (%) 10 (90,2) Sputum results, n (%) 10 (90,2) Sputum results, n (%) 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 10 (90,2) Side effects, n (%) 10 (14,18) Side effects, n (%) 10 (15,6) Liver dysfunction 5 (4,1)	Cardiovascular	6 (4,9)	
Chronic liver disease 6 (4.9) Chronic kidney disease 5 (4,1) Asthma 3 (2,5) Thyroid disease 3 (2,5) Stroke 2 (1,6) TB treatment phase, n (%) 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) 42 (34,2) Yes 40 (32,8) No 82 (67,2) Persistent cough, n (%) 7 Yes 12 (9,8) No 110 (90,2) Sputum results, n (%) 63 (51,6) Positive 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 71 (58,2) Absent 51 (41,8) Side effects, n (%) 63 (2,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Mild 35 (28,7) Mid 35 (28,7) Mid 35 (28,7) Mid 35 (28,7) Mid 32 (25) Present <	Benign hematologic disorder	6 (4,9)	
Chronic kidney disease 5 (4,1) Asthma 3 (2,5) Thyroid disease 3 (2,5) Stroke 2 (1,6) TB treatment phase, n (%) 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) 40 (32,8) No 82 (67,2) Persistent cough, n (%) $2(9,8)$ No 12 (9,8) No 10 (90,2) Sputum results, n (%) 10 (90,2) Sputum results, n (%) 10 (90,2) Sputum results, n (%) 110 (90,2) Absent 51 (41,8) Side effects, n (%) 71 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eyschaitric symptoms 10 (0,8) TB severity, n (%) 73 (30,3) Present 110 (90,2) Types of extra pulmonary TB, n (%) $n = 12$	Chronic liver disease	6 (4,9)	
Asthma $3 (2,5)$ Thyroid disease $3 (2,5)$ Stroke $2 (1,6)$ TB treatment phase, $n (%)$ Intensive Intensive $42 (34,4)$ Maintenance $80 (65,6)$ Retreatment for TB, $n (%)$ $42 (32,8)$ No $82 (67,2)$ Persistent cough, $n (%)$ $110 (90,2)$ Sputum results, $n (%)$ $100 (90,2)$ Sputum results, $n (%)$ $71 (58,2)$ Asbent $71 (58,2)$ Absent $71 (58,2)$ Absent $71 (58,5)$ Allergic reaction $37 (30,3)$ Neurological symptoms $19 (15,6)$ Liver dystunction $5 (4,1)$ Eye problem $3 (2,5)$ Mid $35 (28,7)$ Moderate $50 (41)$ Severe $37 (30,3)$ Present $10 (90,2)$ Type roblem $3 (2,5)$ Mid $35 (28,7)$ Moderate $50 (41)$ Severe $37 (30,3)$ Present $10 (90,2)$ Types of extra pulmonary TB, $n (\%)$ <td>Chronic kidney disease</td> <td>5(4,1)</td> <td></td>	Chronic kidney disease	5(4,1)	
Thyroid disease $3(2,5)$ Stroke $2(1,6)$ TB treatment phase, n (%) Intensive Maintenance $80(65,6)$ Retreatment for TB, n (%) $42(34,4)$ Yes $40(32,8)$ No $82(67,2)$ Persistent cough, n (%) $2(9,8)$ Yes $12(9,8)$ No $110(90,2)$ Sputum results, n (%) $16(13,1)$ Negative $63(51,6)$ No data $43(35,2)$ TB treatment side effects, n (%) $71(58,2)$ Absent $51(41,8)$ Side effects, n (%) $7(30,3)$ Regional and the state of the st	Asthma	3 (2,5)	
Stroke 2 (1,6) TB treatment phase, n (%) Intensive Intensive 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) W Yes 40 (32,8) No 82 (67,2) Persistent cough, n (%) W Yes 12 (9,8) No 110 (90,2) Sputum results, n (%) W Positive 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) T Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) T Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) meant Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Present 12 (9,8) <	Thyroid disease	3 (2,5)	
TB treatment phase, n (%) 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) 40 (32,8) No 82 (67,2) Persistent cough, n (%) 12 (9,8) No 110 (90,2) Sputum results, n (%) 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) Present Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) Gastrointestinal Ary (38,5) Allergic reaction Mild 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) Thereant Moderate 50 (41) Severe 37 (30,3) Present 10 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Absent 10 (90,2) Types of extra pulmon	Stroke	2(1,6)	
Intensive 42 (34,4) Maintenance 80 (65,6) Retreatment for TB, n (%) 7 Yes 40 (32,8) No 82 (67,2) Persistent cough, n (%) 12 (9,8) No 10 (90,2) Sputum results, n (%) 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 71 (58,2) Absent 51 (41,8) Side effects, n (%) 64(1) Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 10 (0,8) TB severity, n (%) 10 (90,2) Midd 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7)	TB treatment phase, n (%)		
Maintenance 80 (65,6) Retreatment for TB, n (%) 40 (32,8) No 82 (67,2) Persistent cough, n (%) 12 (9,8) No 110 (90,2) Sputum results, n (%) 110 (90,2) Sputum results, n (%) 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) $Persent$ Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) $Gastrointestinal$ Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 10 (0,8) TB severity, n (%) $m = 12$ Present 110 (90,2) Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis 5 (41,7) Lymphadenitis 5 (41,7) Lymphadenitis 5 (41,7) Lymphadenitis 5 (41,7) Lymphadenitis 5 (41,	Intensive	42 (34,4)	
Retreatment for TB, n (%) 40 (32,8) Yes 40 (32,8) No 82 (67,2) Persistent cough, n (%) 110 (90,2) Sputum results, n (%) 10 (90,2) Sputum results, n (%) 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 71 (58,2) Absent 51 (41,8) Side effects, n (%) 63 (51,6) Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) 10 (90,2) Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Present 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chorioretinitis 1 (8,3) Meningitis 1 (8,3) Osteomye	Maintenance	80 (65,6)	
Yes 40 (32,8) No 82 (67,2) Persistent cough, n (%) 12 (9,8) Yes 12 (9,8) No 110 (90,2) Sputum results, n (%) Positive Positive 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) Present Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) Gastrointestinal Horigin reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) 10 (8) TB severity n (%) n = 12 Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (4,1,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chrioretinitis 1 (8,3) Osteomyelitis 1 (8,3) <td>Retreatment for TB, n (%)</td> <td></td> <td></td>	Retreatment for TB, n (%)		
No $82 (67,2)$ Persistent cough, n (%) 12 (9,8) No 110 (90,2) Sputum results, n (%) 63 (51,6) Positive 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) Present Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) Gastrointestinal Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) Mid Moderate 50 (41) Severe 37 (30,3) Present 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 3 (25) Chorizoretinitis 1 (8,3) Meningitis 1 (8,3) Osteomyclitis 1 (8,3) Osteomyclitis	Yes	40 (32,8)	
Persistent cough, n (%) 12 (9,8) Yes 12 (9,8) No 110 (90,2) Sputtum results, n (%) 16 (13,1) Positive 16 (13,1) No data 43 (35,2) TB treatment side effects, n (%) 10 Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) 10 Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 10 (0,8) TB severity, n (%) 10 Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 2 (16,7) Absent 10 (9,0,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 1 (8,3) Osteomyclitis 1 (8,3) <tr< td=""><td>No</td><td>82 (67,2)</td><td></td></tr<>	No	82 (67,2)	
Yes 12 (9,8) No 110 (90,2) Sputum results, n (%) Positive Positive 63 (51,6) No data 43 (35,2) B treatment side effects, n (%) Present Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) Gastrointestinal Affect 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) Mild Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Present 10 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 2 (16,7) Absent 1 (8,3) Osteomyelitis 2,35 (0,95-9,22) <	Persistent cough, n (%)		
No $110 (90,2)$ Sputum results, n (%) 16 (13,1) Positive 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 10 (90,2) Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) 63 (51,6) Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) 10 (8) Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chorioretinitis 1 (8,3) Meningitis <	Yes	12 (9.8)	
Sputum results, n (%) 16 (13,1) Positive 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 71 (58,2) Absent 51 (41,8) Side effects, n (%) 63 (51,6) Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) 71 (30,3) Present 50 (41) Severe 37 (30,3) Present 12 (9,8) Absent 110 (90,2) Stypes of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chorizortinitis 1 (8,3) Osteomyelitis 1	No	110 (90.2)	
Positive 16 (13,1) Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 71 (58,2) Absent 51 (41,8) Side effects, n (%) 63 (51,6) Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) 10 (9.8) Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chorioretinitis 1 (8,3) Meningitis 1 (8,3) Meningitis 1 (8,3) Osteomyelitis 1 (8,3) Osteomyelitis 1 (8,3) Neutrophil-Lymphocyte Ratio 2,35 (0,95-	Sputum results. n (%)	- () /	
Negative 63 (51,6) No data 43 (35,2) TB treatment side effects, n (%) 9 Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) 6 Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) 10 (0,8) Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Present 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chorioretinitis 1 (8,3) Meningitis 1 (8,3) Meningitis 1 (8,3) Neutrophil-Lymphocyte Ratio 2,35 (0,95-9,22) Body mass index (kg/m ²), n (%) 20,13 ± 3,506	Positive	16 (13.1)	
No data 43 (35,2) TB treatment side effects, n (%) 71 (58,2) Present 71 (38,5) Absent 51 (41,8) Side effects, n (%) 77 (30,3) Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) Mild Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chorioretinitis 1 (8,3) Meningitis 1 (8,3) Meningitis 1 (8,3) Meningitis 1 (8,3) Osteomyelitis 1 (8,3) Noterothil-Lymphocyte Ratio 2,35 (0,95-9,22) Body mass index (kg/m²), n (%)	Negative	63 (51.6)	
TB treatment side effects, n (%)Present71 (58,2)Absent51 (41,8)Side effects, n (%)73 (30,3)Gastrointestinal47 (38,5)Allergic reaction37 (30,3)Neurological symptoms19 (15,6)Liver dysfunction5 (4,1)Eye problem3 (2,5)Psychiatric symptoms1 (0,8)TB severity, n (%)10,8)TB severity, n (%)71 (30,3)Present50 (41)Severe37 (30,3)Present of extra pulmonary TB, n (%)n = 12Present110 (90,2)Types of extra pulmonary TB, n (%)n = 12Pleuritis5 (41,7)Lymphadenitis2 (16,7)Abdomen/Peritonitis3 (25)Chorioretinitis1 (8,3)Meningitis1 (8,3)Neutrophil-Lymphocyte Ratio2,35 (0,95-9,22)Body mass index (kg/m²), n (%)20,13 ± 3,506< 18.5	No data	43 (35.2)	
Present 71 (58,2) Absent 51 (41,8) Side effects, n (%) 6astrointestinal Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) 10,8) Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Presence of extra pulmonary TB, n (%) n = 12 Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chorioretinitis 1 (8,3) Meningitis 1 (8,3) Meningitis 1 (8,3) Neutrophil-Lymphocyte Ratio 2,35 (0,95-9,22) Body mass index (kg/m²), n (%) 20,13 ± 3,506	TB treatment side effects. n (%)		
Absent $51 (41,8)$ Side effects, n (%) $47 (38,5)$ Gastrointestinal $47 (38,5)$ Allergic reaction $37 (30,3)$ Neurological symptoms $19 (15,6)$ Liver dysfunction $5 (4,1)$ Eye problem $3 (2,5)$ Psychiatric symptoms $1 (0,8)$ TB severity, n (%) $1 (0,8)$ Mild $35 (28,7)$ Moderate $50 (41)$ Severe $37 (30,3)$ Presence of extra pulmonary TB, n (%) $n = 12$ Present $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $20,13 \pm 3,506$	Present	71 (58 2)	
Side effects, n (%) 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) 10 (8) Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Presence of extra pulmonary TB, n (%) n = 12 Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 1 (8,3) Ostcomyelitis 1 (8,3) Neutrophil-Lymphocyte Ratio 2,35 (0,95-9,22) Body mass index (kg/m²), n (%) 20,13 ± 3,506	Absent	51(41.8)	
Gastrointestinal 47 (38,5) Allergic reaction 37 (30,3) Neurological symptoms 19 (15,6) Liver dysfunction 5 (4,1) Eye problem 3 (2,5) Psychiatric symptoms 1 (0,8) TB severity, n (%) Mild Mild 35 (28,7) Moderate 50 (41) Severe 37 (30,3) Presence of extra pulmonary TB, n (%) Present Present 12 (9,8) Absent 110 (90,2) Types of extra pulmonary TB, n (%) n = 12 Pleuritis 5 (41,7) Lymphadenitis 2 (16,7) Abdomen/Peritonitis 3 (25) Chorioretinitis 1 (8,3) Meiningitis 1 (8,3) Osteomyelitis 1 (8,3) Neutrophil-Lymphocyte Ratio 2,35 (0,95-9,22) Body mass index (kg/m²), n (%) 20,13 ± 3,506	Side effects n (%)	01 (11,0)	
Allergic reaction37 (30,3)Neurological symptoms19 (15,6)Liver dysfunction5 (4,1)Eye problem3 (2,5)Psychiatric symptoms1 (0,8)TB severity, n (%) $1 (0,8)$ Mild35 (28,7)Moderate50 (41)Severe37 (30,3)Presence of extra pulmonary TB, n (%) $n = 12$ Present110 (90,2)Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis5 (41,7)Lymphadenitis2 (16,7)Abdomen/Peritonitis3 (25)Chorioretinitis1 (8,3)Osteomyelitis1 (8,3)Neutrophil-Lymphocyte Ratio2,35 (0,95-9,22)Body mass index (kg/m²), n (%)2,35 (0,95-9,22) < 18.5 42 (34,4)	Gastrointestinal	47 (38.5)	
Neurological symptoms19 (15,6)Liver dysfunction $5 (4,1)$ Eye problem $3 (2,5)$ Psychiatric symptoms $1 (0,8)$ TB severity, n (%) $1 (0,8)$ Mild $35 (28,7)$ Moderate $50 (41)$ Severe $37 (30,3)$ Presence of extra pulmonary TB, n (%) $n = 12$ Present $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $20,13 \pm 3,506$	Allergic reaction	37 (30 3)	
Liver dysfunction5 (4,1)Eye problem3 (2,5)Psychiatric symptoms1 (0,8)TB severity, n (%) $1 (0,8)$ Mild35 (28,7)Moderate50 (41)Severe37 (30,3)Presence of extra pulmonary TB, n (%) $12 (9,8)$ Absent110 (90,2)Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis5 (41,7)Lymphadenitis2 (16,7)Abdomen/Peritonitis3 (25)Chorioretinitis1 (8,3)Meningitis1 (8,3)Neutrophil-Lymphocyte Ratio2,35 (0,95-9,22)Body mass index (kg/m²), n (%)20,13 ± 3,506< 18.5	Neurological symptoms	19 (15 6)	
Eve problem $3 (2,5)$ Psychiatric symptoms $1 (0,8)$ TB severity, $n (\%)$ $1 (0,8)$ Mild $35 (28,7)$ Moderate $50 (41)$ Severe $37 (30,3)$ Presence of extra pulmonary TB, $n (\%)$ $n = 12$ Present $110 (90,2)$ Types of extra pulmonary TB, $n (\%)$ $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), $n (\%)$ $20,13 \pm 3,506$ < 18.5	Liver dysfunction	5 (4 1)	
Dyperior $3 (2,6)$ Psychiatric symptoms1 (0,8)TB severity, n (%) $35 (28,7)$ Mild $35 (28,7)$ Moderate $50 (41)$ Severe $37 (30,3)$ Presence of extra pulmonary TB, n (%) $n = 12$ Present $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $20,13 \pm 3,506$ < 18.5	Eve problem	3(2,5)	
TB severity, n (%)T (%)Mild35 (28,7)Moderate50 (41)Severe37 (30,3)Presence of extra pulmonary TB, n (%)12 (9,8)Absent110 (90,2)Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis5 (41,7)Lymphadenitis2 (16,7)Abdomen/Peritonitis3 (25)Chorioretinitis1 (8,3)Meningitis1 (8,3)Osteomyelitis1 (8,3)Neutrophil-Lymphocyte Ratio2,35 (0,95-9,22)Body mass index (kg/m²), n (%)20,13 ± 3,506< 18.5	Psychiatric symptoms	1(0.8)	
Mild $35 (28,7)$ Mild $35 (28,7)$ Moderate $50 (41)$ Severe $37 (30,3)$ Presence of extra pulmonary TB, n (%) $12 (9,8)$ Absent $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $20,13 \pm 3,506$ < 18.5 $42 (34,4)$	TB severity n (%)	1 (0,0)	
Mile $50 (23, 7)$ Moderate $50 (41)$ Severe $37 (30,3)$ Presence of extra pulmonary TB, n (%) $12 (9,8)$ Absent $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $42 (34,4)$ < 18.5 $90 (65.6)$	Mild	35 (28.7)	
Nicelate $37 (30,3)$ Presence of extra pulmonary TB, n (%) $12 (9,8)$ Present $12 (9,8)$ Absent $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $42 (34,4)$ < 18.5 $42 (34,4)$	Moderate	50 (41)	
Develop $D(50,5)$ Presence of extra pulmonary TB, n (%) $12 (9,8)$ Absent $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $42 (34,4)$ ≥ 18.5 $42 (34,4)$	Severe	37(303)	
Present $12 (9,8)$ Absent $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $42 (34,4)$ > 18.5 $42 (34,4)$	Presence of extra pulmonary TB $n(\%)$	57 (50,5)	
Absent $112 (0,0)$ Absent $110 (90,2)$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $42 (34,4)$ > 18.5 $90 (45.6)$	Present	12 (9.8)	
Hosen $n = 12$ Types of extra pulmonary TB, n (%) $n = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $20,13 \pm 3,506$ < 18.5	Absent	12(9,0) 110(902)	
Types of extra pullionary TB, fr (76) $fr = 12$ Pleuritis $5 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $20,13 \pm 3,506$ < 18.5	Types of extra pulmonary TP $n(0/2)$	n = 12	
Fredritis $3 (41,7)$ Lymphadenitis $2 (16,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $20,13 \pm 3,506$ < 18.5	Disputitional pullionary 1D, II (70)	11 - 12 5 (41.7)	
Lymphademus $2 (10,7)$ Abdomen/Peritonitis $3 (25)$ Chorioretinitis $1 (8,3)$ Meningitis $1 (8,3)$ Osteomyelitis $1 (8,3)$ Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m²), n (%) $20,13 \pm 3,506$ < 18.5	r leulius Lymphodonitic	3(41,7) 2(16,7)	
Abdomen/Fertomus $3 (23)$ Chorioretinitis1 (8,3)Meningitis1 (8,3)Osteomyelitis1 (8,3)Neutrophil-Lymphocyte Ratio2,35 (0,95-9,22)Body mass index (kg/m²), n (%)20,13 ± 3,506< 18.5	Abdoman/Deritanitis	2(10,7) 2(25)	
Chornoretinitis 1 (6,3) Meningitis 1 (8,3) Osteomyelitis 1 (8,3) Neutrophil-Lymphocyte Ratio 2,35 (0,95-9,22) Body mass index (kg/m ²), n (%) 20,13 ± 3,506 < 18.5	Abdomen/rentomus Chariaratinitia	5(23)	
Mennights 1 (6,3) Osteomyelitis 1 (8,3) Neutrophil-Lymphocyte Ratio $2,35 (0,95-9,22)$ Body mass index (kg/m ²), n (%) $20,13 \pm 3,506$ < 18.5	Moningitig	1(0,3) 1(2,3)	
Neutrophil-Lymphocyte Ratio 2,35 (0,95-9,22) Body mass index (kg/m ²), n (%) $20,13 \pm 3,506$ < 18.5	Nichinguis Osteomyalitis	1(0,3) 1(0,2)	
Neurophil-Lymphocyte Kato $2,35 (0,95-9,22)$ Body mass index (kg/m ²), n (%) $20,13 \pm 3,506$ < 18.5	Usicollycillis Neutrophil Lympheavite Datia	1 (8,3)	2.25(0.05,0.22)
Body mass index (kg/m ²), n ($\%$) < 18.5 > 18.5 > 20,13 ± 3,506 42 (34,4) > 0 ((5.6))	$\frac{1}{1} = \frac{1}{1} = \frac{1}$		2,35 (0,95-9,22)
> 10.3 $42(54,4)$ > 19.5 $90(65.6)$	bouy mass index (Kg/m ²), n (0)	42 (24 4)	$20,13 \pm 3,306$
VIII WE WY	> 10.J > 18 5	42 (34,4)	

Table 1 (continued). Study participant characteristics

Characteristics	N =122	Mean ± SD / median (min-max)
Depression, n (%)		
Present	59 (48,4)	
Absent	63 (51,6)	
Depression severity n (%)	n = 59	
Mild	34 (57,6)	
Moderate	16 (27,1)	
Severe	9 (15,3)	

Table 1 (continued). Study participant characteristics

Table 2. Bivariate analysis

Variables Present Absent P Gender, n (%) Female 32 (54,2) 31 (49,2) 0,578	(IK 95%) 1,223 0,601-2,492)
Gender, n (%) 32 (54,2) 31 (49,2) 0,578	1,223),601-2,492)
Female32 (54,2)31 (49,2)0,578	1,223),601-2,492)
),601-2,492)
Male $27(45.8)$ $32(50.8)$ (0	, , ,
Age. n (%)	
$\geq 60 \text{ years}$ 13 (22) 7 (11,1) 0,103	2,261
< 60 years $46 (78)$ $56 (88.9)$ (0),833-6,135)
Educational level n (%)	, , ,
Not Finished 9 years basic program $10(16.9)$ $3(4.8)$ 0.029	4.082
Finished 9 years basic program $49(83.1)$ $60(95.2)$ (1)	.064-15.655)
Marital status n (%)	,,
Married/had married 45 (76.3) 44 (69.8) 0.424	1.388
Single $14(23.7)$ 19(30.2) (0	0.62-3.107)
Income level n (%)	
Minimum wage $43(72.9)$ $38(60.3)$ 0.142	1 768
Above minimum wage $16(27.1)$ $25(39.7)$ (0).823-3.797)
BMI n (%)	····
$< 18.5 \text{ kg/m}^2$ 22 (37.3) 20 (32.3) 0.561	1.249
$> 18.5 \text{ kg/m}^2$ $37 (62.7)$ $42 (67.7)$ (0).590-2.642)
Chronic disease comorbidity n (%)	, , ,
Present $54(91.5)$ $29(46) < 0.001$	12.662
Absent $5(8.5)$ $34(54)$ (4.	.468-35.880)
TB treatment phase. n (%)	, , ,
Intensive 21 (35.6) 21 (33.3) 0.793	1.105
Maintenance $38(64,4)$ $42(66,7)$ (0),524-2,333)
Retreatment for TB. n (%)	, , ,
Yes 23 (39) 17 (27) 0,158	1,729
No 36 (61) 46 (73) (0),806-3,710)
Persistent cough, n (%)	, , ,
Yes 6(10,2) 6(9.5) 0,905	1,075
No 53 (89,8) 57 (90.5) (0),327-3,541)
TB treatment side effects. n (%)	, , ,
Present $47(79.7)$ $24(38.1) < 0.001$	6,365
Absent $12(20,3)$ $39(61.9)$ (2	2,84-14,345)
TB severity, n (%)	,
Moderate - severe 46 (78) 41 (65.1) 0,116	1,899
Mild 13 (22) 22 (34.9) (0),849-4,245)
Neutrophil-Lymphocyte ratio, 2.53 (1,14-9,22) 2.15 (0.95-5.62) 0,101 (0.95-5.62)	. ,

Table 3. Multivariate analysis

Variables	Р	OR (IK 95%)
Age \geq 60 years old	0,694	1,30 (0,35 – 4,88)
Low educational status	0,057	4,78 (0,95 - 23,95)
Minimum wage	0,564	1,35 (0,49 – 3,76)
Presence of chronic disease comorbidity	< 0,001	12,90 (4,01 – 41,50)
On retreatment for TB	0,684	0,81 (0,29 – 2,25)
Presence of TB treatment side effects	< 0,001	7,13 (2,67 – 19,03)
More severe form of TB infection	0,09	2,44 (0,87 - 6,84)
Higher Neutrophil-Lymphocyte ratio	0,300	0,84 (0,60 - 1,17)

DISCUSSION

The proportion of depression in this study is 48.4%. This is similar with previous study done by Ige, et al⁴ who found the prevalence of depression is 45.5%, and study conducted by Buberwa¹² who found that the prevalence of depression is 46.9%. Our study result is not much different from previous study conducted in Indonesia by Nahda, et al¹⁴ who found the prevalence of depression is 67.4% among pulmonary TB patients.

Having chronic disease comorbidity is related to depression from our study. This finding agrees with other studies.^{6,14} Depression is known to be related to chronic disease and can influence treatment adherence, and also relationship with the health workers. Patients with depression will develop high risk behavior such as sedentary lifestyle and tendency toward smoking.¹⁹ Other study also showed that the risk of depression will increase with multiple comorbidities.²⁰

Side effects of TB treatment also a significant factor related to depression from our study. This finding also agrees with previous studies.^{11,13,21} The most side effects experienced by our study participants are gastrointestinal disturbance, particularly nausea. This finding maybe caused by the fact that many of our study participant consumes other drugs related to their comorbidities. Having treatment side effects will cause significant stress and also negative perception toward the TB treatment itself, causing increased risk of having depression.

Different from study conducted by Kehbila, et al,⁶ female gender is not related to depression from our study. In pulmonary TB population, gender influence to depression are still debatable. Other study conducted by Sulehri, et al² found that male gender is more prone to depression. They tend to be depressed when having pulmonary TB infection because of the limitation in work, and also higher responsibilities in their family economic condition. They also face higher risk of stigmatization from the community.

Other factors evaluated in our study which include older age, low educational status, underweight, and being on retreatment for TB infection are not related to depression in our study. This difference from other studies may be caused of different sample size which can affect the power of this study.^{3,4,6,11}

From our study, having low income does not related to depression, eventhough most of our study participant have minimum wage. This finding also differ from previous study by Issa, et al⁵, and Sulehri, et al.² From literature, the psychological effect and burden of poverty will significantly increase stress in TB patients. Our finding can be caused by the national health insurance owned by > 95% of our study population. This may be the cause of the different result in our study, because having health insurance significantly reduce the cost of treatment needed by patients.

Tuberculosis treatment phase, and persistent cough symptoms are not related with depression in this study. This finding also differ from previous study by Buberwa, et al,¹² and Mandaknali, et al.¹¹ Their study found that being in the intensive phase of TB treatment, are related to depression. Our study have different results from the previous study because we exclude subjects who has history of hospital admission in the last month. Therefore, most of our study participant are already in the maintenance phase of TB treatment and only few of them still having cough symptoms because of this exclusion criteria. Another cause of this difference is the characteristic of pulmonary TB patients in Cipto Mangunkusumo hospital. Many of our pulmonary TB patients diagnosed without classical symptoms such as chronic cough, but based on incidental finding or TB screening when doing the perioperative assessment or before giving chemotherapy or immunosuppressive agent.

We determined the degree of TB infection based on the initial symptoms and radiological features at first time diagnosis, meanwhile, our study participants are mostly in the maintenance phase. This may cause the difference between our findings compared to previous study regarding the degree of TB infection. The study conducted by Panchal¹⁵ found that the degree of TB infection are related to depression. More severe form of TB infection related to greater suffering, and consequent strain on psychological coping mechanism.

Neutrophil-Lymphocyte ratio are not related to depression in our study. Even though the median of NLR in the depressed group is higher than the non-depressive group, this result are not statistically significant. This finding did not agree with previous studies which showed that patient with depression will have increased NLR.^{22,23} From literature, we also know that NLR increased in chronic diseases such as diabetes,²⁴ systemic lupus erythematosus,²⁵ and malignancy.²⁶ The different result from our study may be caused by the number of samples, even though many of our study participant has chronic diseases comorbidities.

STUDY LIMITATION

This study used structured interview according to the DSM-V criteria of depression, and stratified depression using the validated BDI-II questionnaire for Indonesian population. This study also the first study who analyses NLR in TB patients with depression. Nevertheless, this study is a cross sectional study, so we can't explain the temporal relationship between the variables and depression. This study also takes place in only one centre which is Cipto Mangunkusumo hospital. The characteristic of pulmonary TB patients in this hospital is quite different from the population because of the many comorbidities, and the non-classical symptoms of TB infection. Because of this reason, the result of this study can't be generalized to all the non-MDR pulmonary TB patients.

CONCLUSION

The proportion of depression in nonmultidrug-resistant pulmonary TB patients in Cipto Mangunkusumo hospital is 48,4%. Having chronic disease comorbidities, and experiencing side effects of TB treatment are related with depression in non-multidrugresistant pulmonary TB patients in Cipto Mangunkusumo hospital.

REFERENCES

- Shen T, Wang C, Lin C, Liao W, Chen C, Tu C, et al. People with tuberculosis are associated with a subsequent risk of depression. Eur J Intern Med. 2014;25(10):936–40.
- Sulehri MA, Dogar IA, Sohail H, Mehd Z, Azam M, Niaz O, et al. Prevalence of depression among tuberculosis patients. APMC. 2010;4(2):133–7.
- Ambaw F, Mayston R, Hanlon C, Alem A. Burden and presentation of depression among newly diagnosed individuals with TB in primary care settings in Ethiopia. BMC Psychiatry. 2017;17(57):1–10.
- 4. Ige OM, Lasebikan VO. Prevalence of depression in tuberculosis patients in comparison with non-tuberculosis family contacts visiting the DOTS clinic in a Nigerian tertiary care hospital and its correlation with disease pattern. Ment Health Fam Med. 2011;8(4):235–41.
- 5. Issa BA, Yussuf AD, Kuranga SI. Depression comorbidity among patients with tuberculosis in a university teaching hospital outpatient clinic in Nigeria. Ment Health Fam Med. 2009;6(3):133–8.
- 6. Kehbila J, Ekabe CJ, Aminde LN, Noubiap JJN, Fon PN. Prevalence and correlates of depressive symptoms in adult patients with pulmonary tuberculosis in the Southwest Region of Cameroon. Infect Dis Poverty. 2016;5(1):51.

- 7. Basuki R, Rihadini, Budhiarti E. Pengaruh depresi terhadap kepatuhan minum OAT pada penderita TB. J Kedokt Muhammadiyah. 2014;3(2):1–8.
- Aamir S, Aisha. Co-morbid anxiety and depression among pulmonary tuberculosis patients. J Coll Physicians Surg Pakistan. 2010;20(10):703–4.
- 9. Pachi A, Bratis D, Moussas G, Tselebis A. Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients. Tuberc Res Treat. 2013;2013:489865.
- Sweetland A, Oquendo M, Wickramaratne P, Weissman M, Wainberg M. Depression: A silent driver of the global tuberculosis epidemic. World Psychiatry. 2014;13(3):325–6.
- Mandaknalli R, Giriraj B. Prevalence of depression in tuberculosis patients in a tertiary care hospital. Sch J Appl Med Sci. 2015;3(6D):2445–8.
- 12. Buberwa G. Prevalence of depression and associated factors among tuberculosis patients attending in clinics Temeke municipality, Dar es Salaam, Tanzania Muhimbili [Internet]. University of and 2013. Health Allied sciences; Available from:http://ir.muhas.ac.tz:8080/ jspui/bitstream/123456789/1686/1/ GilbertBuberwa.pdf
- Basu G, Chatterjee C, Singh R, Biswas S. Prevalence of depression in tuberculosis patients: An experience from a DOTS clinic. IJRRMS. 2012;2(4):14–7.
- Nahda ND, Kholis FN, Wardani ND, Hardian. Faktor-faktor yang berpengaruh terhadap kejadian depresi pada pasien tuberkulosis di RSUPDr. Kariadi Semarang. J Kedokt Diponegoro. 2017;6(4):1529–42.
- Panchal SL. Correlation with duration and depression in TB Patients in Rural Jaipur District (NIMS hospital). Int J Pharma Bio Sci. 2011;2(2):263–7.
- Blume J, Douglas SD, Evans DL. Immune Suppression and Immune Activation in Depression. Brain Behav Immun. 2012;25(2):221–9.
- 17. Sunbul EA, Sunbul M, Yanartas O, Cengiz F, Bozbay M, Sari I, et al. Increased

neutrophil/lymphocyte ratio in patients with depression is correlated with the severity of depression and cardiovascular risk factors. Psychiatry Investig. 2016;13(1):121–6.

- 18. Ginting H, Näring G, van der Veld WM, Srisayekti W, Becker ES. Validating the Beck Depression Inventory-II in Indonesia's general population and coronary heart disease patients. Int J Clin Heal Psychol. 2013;13(3):235–42.
- Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54(3):216– 26.
- 20. Boing AF, Melo GR, Boing AC, Moretti-Pires RO, Peres KG, Peres MA. Association between depression and chronic diseases: Results from a population-based study. Rev Saúde Pública. 2012;46(4):617–23.
- 21. Lee E. Prevalence of depression among active TB and TB/HIV patients in Kisumu County [Internet]. Independent Study Project (ISP) Collection. 2015. Available from: http://digitalcollections.sit.edu/isp_ collection/2152
- 22. Demir S, Atli A, Bulut M, İbiloğlu AO, Güneş M, Kaya MC, et al. Neutrophil– lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy. Neuropsychiatr Dis Treat. 2015;11(Aug):2253–8.
- 23. Ayhan MG, Cicek IE, Inanli I, Caliskan AM, Ercan SK, Eren I. Neutrophil/lymphocyte and platelet/lymphocyte ratios in all mood states of bipolar disorder. Psychiatry Clin Psychopharmacol. 2017;27(3):284–8.
- 24. Mertoglu C, Gunay M. Neutrophillymphocyte ratio and platelet-lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab Syndr Clin Res Rev [Internet]. 2017;11(Suppl 1):S127–31. Available from: http://dx.doi.org/10.1016/j.dsx.2016.12.021
- 25. Gorial FI. A clinical utility of neutrophil lymphocyte ratio as a prognostic indicator of systemic lupus erythematosus disease activity. J Pharm Sci Res. 2018;10(3):637–9.
- 26. Li X, Dai D, Chen B, Tang H, Xie X, Wei W. The value of neutrophil-to-lymphocyte

ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. J Cancer. 2018;9(5):861–71.